A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we offer the Guardant360 Liquid test, formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, colorectal cancer and breast cancer.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 982M | 982M | 739M | 564M | 450M | 374M |
| Net Income | -416M | -416M | -436M | -479M | -655M | -406M |
| EPS | $-3.32 | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
| Free Cash Flow | -233M | -233M | -275M | -345M | -387M | -284M |
| ROIC | -28.7% | -34.6% | -43.5% | -36.9% | -54.7% | -22.8% |
| Gross Margin | 64.5% | 64.5% | 60.8% | 0.7% | 7.1% | 22.4% |
| Debt/Equity | 0.00 | -16.94 | -9.36 | 8.36 | 22.39 | 2.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -437M | -437M | -444M | -565M | -544M | -411M |
| Operating Margin | -44.5% | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% |
| ROE | 0.0% | - | - | -302.1% | -1087.7% | -62.9% |
| Shares Outstanding | 125M | 125M | 123M | 112M | 102M | 101M |
Guardant Health, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 31.1%. Total shareholder yield (buybacks) is 0.4%.
Guardant Health, Inc. (GH) has a 5-year average return on invested capital (ROIC) of -38.5%. This is below average and may indicate limited pricing power.
Guardant Health, Inc. (GH) has a market capitalization of $10.8B. It is classified as a large-cap stock.
Guardant Health, Inc. (GH) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.42%.
Guardant Health, Inc. (GH) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
Guardant Health, Inc. (GH) reported annual revenue of $982 million in its most recent fiscal year, based on SEC EDGAR filings.
Guardant Health, Inc. (GH) has a net profit margin of -42.4%. The company is currently unprofitable.
Guardant Health, Inc. (GH) generated $-233 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Guardant Health, Inc. (GH) reported earnings per share (EPS) of $-3.32 in its most recent fiscal year.
Guardant Health, Inc. (GH) has a 5-year average gross margin of 31.1%. This indicates decent pricing power.
The Ledger Terminal provides 9 years of financial data for Guardant Health, Inc. (GH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Guardant Health, Inc. (GH) has a book value per share of $-0.79, based on its most recent annual SEC filing.